Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2023 | What are the potential applications of MYC inhibition in oncology?

Laura Soucek, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the future of OMO-103, a novel MYC inhibitor, and the potential indications it could be approved for. Whilst the drug can be used in all MYC-mutant tumors, pancreatic ductal adenocarcinoma (PADC) and non-small cell lung cancer (NSCLC) have been found to be particularly responsive to OMO-103. Combination therapies with chemotherapy or KRAS inhibitors in PADC and NSCLC respectively are additionally being assessed. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.